Shenzhen Kangtai Biological Products Co., Ltd. (SHE:300601)

China · Delayed Price · Currency is CNY

12.58

-0.29 (-2.25%)

Sep 4, 2026, 3:04 PM CST

Market Cap	14.05B -35.5%
Revenue (ttm)	2.55B -10.1%
Net Income	83.18M +12.6%
EPS	0.08 +28.1%
Shares Out	1.12B
PE Ratio	158.87
Forward PE	71.60
Dividend	0.05 (0.42%)
Ex-Dividend Date	Jun 11, 2026

Volume	16,593,959
Open	13.57
Previous Close	12.87
Day's Range	12.56 - 13.57
52-Week Range	10.70 - 20.17
Beta	0.63
Analysts	Buy
Price Target	15.11 (+20.11%)
Earnings Date	Aug 22, 2026

About SHE:300601

Shenzhen Kangtai Biological Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of human vaccines in China and internationally. The company offers 13-valent pneumococcal polysaccharide conjugate vaccines (TT/DT); varicella vaccines (freeze-dried); hepatitis B vaccines; 23-valent pneumococcal polysaccharide vaccines; diphtheria tetanus acellular pertussis and haemophilus influenzae type B combined vaccines; diphtheria, tetanus, and acellular pertussis combined vaccine, adsorbed; rabies v... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1992

Employees 1,957

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300601

Full Company Profile

Financial Performance

In 2025, SHE:300601's revenue was 2.67 billion, an increase of 0.81% compared to the previous year's 2.65 billion. Earnings were 70.33 million, a decrease of -65.12%.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for 300601 stock is "Buy." The 12-month stock price target is ¥15.11, which is an increase of 20.11% from the latest price.

Price Target

¥15.11

(20.11% upside)

Analyst Consensus: Buy

Stock Forecasts